SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody

Dou,Xiaofeng; Yan,Jianghua; Zhang,Yafei; Liu,Peng; Jiang,Yizhen; Lv,Sha; Zeng,Fanwei; Chen,Xiaoli; Wang,Shengyu; Zhang,Haipeng; Wu,Hua; Zhang,Hong; Ouyang,Lin; Su,Xinhui

doi:10.3892/ijo.2016.3579

SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody

Authors:
- Xiaofeng Dou
- Jianghua Yan
- Yafei Zhang
- Peng Liu
- Yizhen Jiang
- Sha Lv
- Fanwei Zeng
- Xiaoli Chen
- Shengyu Wang
- Haipeng Zhang
- Hua Wu
- Hong Zhang
- Lin Ouyang
- Xinhui Su
View Affiliations

Affiliations: Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, Fujian 361004, P.R. China, Cancer Research Center of Medical School, Xiamen University, Xiamen, Fujian 361102, P.R. China, Department of Nuclear Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China, Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310052, P.R. China, Department of Imaging Medicine, Affiliated Southeast Hospital of Xiamen University, Zhangzhou, Fujian 363000, P.R. China
Published online on: June 16, 2016 https://doi.org/10.3892/ijo.2016.3579
Pages: 961-970

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a novel co-receptor for vascular endothelial growth factor (VEGF), neuropilin receptor type-1 (NRP-1) is overexpressed in several cancers and metastases, and serves as an attractive target for cancer molecular imaging and therapy. Previous single photon emission computerized tomography (SPECT) studies demonstrated that the small NRP-1-targeting peptides 99mTc-MA-ATWLPPR and 99mTc-CK3 showed poor tumor imaging quality, because of their rapid blood clearance and very low tumor uptake. Compared with small peptides, monoclonal antibodies (mAbs) can improve imaging of NRP-1-expression, due to their high affinity, specificity and slow extraction. A6-11-26 is a novel monoclonal antibody against NRP-1 b1b2 domain that exhibits inhibition of tumor growth in NPR-1-expressing preclinical models. The aim of the present study was to develop the 131I-labeled anti-NRP-1 monoclonal antibody A6-11-26 as a SPECT probe for imaging of NRP-1-positive tumor. An anti-NRP-1 monoclonal antibody (A6-11-26) was produced by hybridomas and was labeled with iodine-131 by the iodogen method. In vitro, the radiolabeling efficiency, radiochemical purity, immunoreactive fraction and stability were assessed. Binding affinity and specificity of 131I‑A6-11-26 to NRP-1 were evaluated using human glioblastoma U87MG cells. In vivo, biodistribution and SPECT/CT studies were conducted on mice bearing U87MG xenografts after the injection of 131I-A6-11-26 with or without co-injection of unlabeled A6-11-26 antibody. A6-11-26 was generated successfully by hybridoma with high purity (>95%) and was labeled with iodine-131 within 60 min with high labelling efficiency (95.46±3.34%), radiochemical purity (98.23±1.41%). 131I-A6-11-26 retained its immunoreactivity and also displayed excellent stability in mouse serum and PBS solution during 1 to 96 h. Cell uptake assays showed high NRP-1-specific uptake (15.80±1.30% applied activity at 6 h) in U87MG cells. 131I-A6-11-26 bound to NRP-1 with low nanomolar affinity (KD=1.67±0.14 nM) in U87MG cells. In vivo, biodistribution study demonstrated targeting of U87MG glioma xenografts was NRP-1 specific. The tumor uptake was 6.00±1.24%ID/g at 24 h, and the tumor to muscle ratio was 3.20±0.30 at 24 h, and reached the highest level of 6.13±0.24 at 120 h after injection. SPECT imaging studies revealed that 131I-A6-11-26 could clearly identify U87MG tumors with good contrast, especially at 72-120 h after injection. The present study demonstrates that 131I-A6-11-26 is capable of detecting lesions in an NRP-1-expressing tumor with high target selectivity, and may offer a promising SPECT agent for NRP-1 expression positive tumor and encourage further investigation.

View Figures

View References

1	Gilbert MR: Renewing interest in targeting angiogenesis in glioblastoma. Lancet Oncol. 15:907–908. 2014. View Article : Google Scholar : PubMed/NCBI
2	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
3	Spratlin JL, Mulder KE and Mackey JR: Ramucirumab (IMC-1121B): A novel attack on angiogenesis. Future Oncol. 6:1085–1094. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
5	Inoue M, Hager JH, Ferrara N, Gerber HP and Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 1:193–202. 2002. View Article : Google Scholar : PubMed/NCBI
6	Otrock ZK, Makarem JA and Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
7	Cudmore MJ, Hewett PW, Ahmad S, Wang KQ, Cai M, Al-Ani B, Fujisawa T, Ma B, Sissaoui S, Ramma W, et al: The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun. 3:9722012. View Article : Google Scholar : PubMed/NCBI
8	Mac Gabhann F and Popel AS: Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: A computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol. 292:H459–H474. 2007. View Article : Google Scholar
9	Gluzman-Poltorak Z, Cohen T, Herzog Y and Neufeld G: Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem. 275:18040–18045. 2000. View Article : Google Scholar : PubMed/NCBI
10	Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, et al: Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: Prognostic significance and relationship with markers for aggressiveness. Histopathology. 61:350–364. 2012. View Article : Google Scholar : PubMed/NCBI
11	Nakayama T, Cho YC, Mine Y, Yoshizaki A, Naito S, Wen CY and Sekine I: Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol. 12:6182–6187. 2006. View Article : Google Scholar : PubMed/NCBI
12	Staton CA, Kumar I, Reed MW and Brown NJ: Neuropilins in physiological and pathological angiogenesis. J Pathol. 212:237–248. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bagri A, Tessier-Lavigne M and Watts RJ: Neuropilins in tumor biology. Clin Cancer Res. 15:1860–1864. 2009. View Article : Google Scholar : PubMed/NCBI
14	Pellet-Many C, Frankel P, Jia H and Zachary I: Neuropilins: Structure, function and role in disease. Biochem J. 411:211–226. 2008. View Article : Google Scholar : PubMed/NCBI
15	Prud’homme GJ and Glinka Y: Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 3:921–939. 2012. View Article : Google Scholar
16	Chaudhary B, Khaled YS, Ammori BJ and Elkord E: Neuropilin 1: Function and therapeutic potential in cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
17	Plein A, Fantin A and Ruhrberg C: Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. Microcirculation. 21:315–323. 2014. View Article : Google Scholar : PubMed/NCBI
18	Sulpice E, Plouët J, Bergé M, Allanic D, Tobelem G and Merkulova-Rainon T: Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood. 111:2036–2045. 2008. View Article : Google Scholar
19	Geretti E, Shimizu A and Klagsbrun M: Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 11:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
20	Parker MW, Xu P, Li X and Vander Kooi CW: Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem. 287:11082–11089. 2012. View Article : Google Scholar : PubMed/NCBI
21	Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
22	Fuh G, Garcia KC and de Vos AM: The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem. 275:26690–26695. 2000.PubMed/NCBI
23	Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T and Fujisawa H: A requirement for neuropilin-1 in embryonic vessel formation. Development. 126:4895–4902. 1999.PubMed/NCBI
24	Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, Tamagnone L and Alitalo K: Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 20:1462–1472. 2006. View Article : Google Scholar : PubMed/NCBI
25	Herzog Y, Kalcheim C, Kahane N, Reshef R and Neufeld G: Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev. 109:115–119. 2001. View Article : Google Scholar : PubMed/NCBI
26	Kim YJ, Bae J, Shin TH, Kang SH, Jeong M, Han Y, Park JH, Kim SK and Kim YS: Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis. J Control Release. 216:56–68. 2015. View Article : Google Scholar : PubMed/NCBI
27	Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, et al: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007. View Article : Google Scholar : PubMed/NCBI
28	Caunt M1, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al: Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell. 13:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhang Y, Liu P, Jiang Y, Dou X, Yan J, Ma C, Fan Q, Wang W, Su F, Tang H, et al: High expression of neuropilin-1 associates with unfavorable clinicopathological features in hepatocellular carcinoma. Pathol Oncol Res. 22:367–375. 2016. View Article : Google Scholar
30	Xu Y, Li P, Zhang X, Wang J, Gu D and Wang Y: Prognostic implication of neuropilllin-1 up-regulation in human nasopharyngealc arcinoma. Diagn Pathol. 8:1552013. View Article : Google Scholar
31	Cheng W, Fu D, Wei ZF, Xu F, Xu XF, Liu YH, Ge JP, Tian F, Han CH, Zhang ZY, et al: NRP-1 expression in bladder cancer and its implications for tumor progression. Tumour Biol. 35:6089–6094. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhu H, Cai H, Tang M and Tang J: Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis. Clin Transl Oncol. 16:732–738. 2014. View Article : Google Scholar
33	Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, et al: A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs. 32:653–660. 2014. View Article : Google Scholar : PubMed/NCBI
34	Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, et al: A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 73:951–960. 2014. View Article : Google Scholar : PubMed/NCBI
35	Tolmachev V, Stone-Elander S and Orlova A: Current approaches to the use of radiolabeled tyrosine kinase-targeting drugs for patient stratification and treatment response monitoring: Prospects and pitfalls. Lancet Oncol. 11:992–1000. 2010. View Article : Google Scholar : PubMed/NCBI
36	Perret GY, Starzec A, Hauet N, Vergote J, Le Pecheur M, Vassy R, Léger G, Verbeke KA, Bormans G, Nicolas P, et al: In vitro evaluation and biodistribution of a ^99mTc-labeled anti-VEGF peptide targeting neuropilin-1. Nucl Med Biol. 31:575–581. 2004. View Article : Google Scholar : PubMed/NCBI
37	Feng GK, Liu RB, Zhang MQ, Ye XX, Zhong Q, Xia YF, Li MZ, Wang J, Song EW, Zhang X, et al: SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide. J Control Release. 192:236–242. 2014. View Article : Google Scholar : PubMed/NCBI
38	Li X, Luo F, Wang S, Ni E, Tang X, Lv H, Chen X, Chen L and Yan J: Monoclonal antibody against NRP-1 b1b2. Hybridoma (Larchmt). 30:369–373. 2011. View Article : Google Scholar
39	Chen L, Miao W, Tang X, Zhang H, Wang S, Luo F and Yan J: Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice. J Biomedical Nanotechnol. 9:551–558. 2013. View Article : Google Scholar
40	Zeng F, Luo F, Lv S, Zhang H, Cao C, Chen X, Wang S, Li Z, Wang X, Dou X, et al: A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway. Anticancer Drugs. 25:663–672. 2014.PubMed/NCBI
41	Yang C, Yun Q, Sun H, Yang G, Liang T, Zhang C, Song J, Han J and Hou G: Non-invasive imaging of Toll-like receptor 5 expression using ¹³¹I-labeled mAb in the mice bearing H22 tumors. Oncol Lett. 7:1919–1924. 2014.PubMed/NCBI
42	Lindmo T, Boven E, Cuttitta F, Fedorko J and Bunn PA Jr: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 72:77–89. 1984. View Article : Google Scholar : PubMed/NCBI
43	Malviya G1, Anzola KL, Podestà E, Laganà B, Del Mastro C, Dierckx RA, Scopinaro F and Signore A: ^99mTc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol. 14:637–646. 2012. View Article : Google Scholar
44	Su X, Cheng K, Jeon J, Shen B, Venturin GT, Hu X, Rao J, Chin FT, Wu H and Cheng Z: Comparison of two site-specifically ¹⁸F-labeled affibodies for PET imaging of EGFR positive tumors. Mol Pharm. 11:3947–3956. 2014. View Article : Google Scholar : PubMed/NCBI
45	Zhao Q, Yan P, Wang RF, Zhang CL, Li L and Yin L: A novel ^99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: A pilot study. PLoS One. 8:e610432013. View Article : Google Scholar
46	Su X, Cheng K, Liu Y, Hu X, Meng S and Cheng Z: PET imaging of insulin-like growth factor type 1 receptor expression with a ⁶⁴Cu-labeled Affibody molecule. Amino Acids. 47:1409–1419. 2015. View Article : Google Scholar : PubMed/NCBI
47	Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, et al: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol. 37:785–794. 2010. View Article : Google Scholar : PubMed/NCBI
48	Wang X, Aldrich MB, Marshall MV and Sevick-Muraca EM: Preclinical characterization and validation of a dual-labeled trastuzumab-based imaging agent for diagnosing breast cancer. Chin J Cancer Res. 27:74–82. 2015.PubMed/NCBI
49	Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil FP, Fielder PJ, et al: Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol. 166:368–377. 2012. View Article : Google Scholar :
50	van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG and Perk LR: Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist. 12:1379–1389. 2007. View Article : Google Scholar
51	Li X, Gong M, Xu W and Tang L: Market dynamics of antibody drugs in both domestic and abroad. Drugs Clin. 27:185–191. 2012.
52	Bergé M, Allanic D, Bonnin P, de Montrion C, Richard J, Suc M, Boivin JF, Contrerès JO, Lockhart BP, Pocard M, et al: Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J Hepatol. 55:866–875. 2011. View Article : Google Scholar : PubMed/NCBI
53	Han Z, Jiang G, Zhang Y, Xu J, Chen C, Zhang L, Xu Z and Du X: Effects of RNA interference-mediated NRP-1 silencing on the proliferation and apoptosis of breast cancer cells. Mol Med Rep. 12:513–519. 2015.PubMed/NCBI
54	Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, et al: Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 93:233–241. 2005. View Article : Google Scholar : PubMed/NCBI
55	Yue B, Ma JF, Yao G, Yang MD, Cheng H and Liu GY: Knockdown of neuropilin-1 suppresses invasion, angiogenesis, and increases the chemosensitivity to doxorubicin in osteosarcoma cells: an in vitro study. Eur Rev Med Pharmacol Sci. 18:1735–1741. 2014.
56	Mehta S, Moon J, Hashmi M, Leblanc M, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK and Williamson S: Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: A study based on SWOG protocol S0420. Oncol Rep. 29:2095–2100. 2013.PubMed/NCBI